Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0ZE1O
|
|||
| Former ID |
DNCL002638
|
|||
| Drug Name |
Plinabulin
|
|||
| Synonyms |
NPI-2358
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 3 | [1] | |
| Company |
Nereus Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H20N4O2
|
|||
| Canonical SMILES |
CC(C)(C)C1=C(N=CN1)C=C2C(=O)NC(=CC3=CC=CC=C3)C(=O)N2
|
|||
| InChI |
1S/C19H20N4O2/c1-19(2,3)16-13(20-11-21-16)10-15-18(25)22-14(17(24)23-15)9-12-7-5-4-6-8-12/h4-11H,1-3H3,(H,20,21)(H,22,25)(H,23,24)/b14-9-,15-10-
|
|||
| InChIKey |
UNRCMCRRFYFGFX-TYPNBTCFSA-N
|
|||
| CAS Number |
CAS 714272-27-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14924620, 24220275, 75782763, 99431571, 99437014, 103751458, 109692962, 124490395, 124757055, 125163859, 131480719, 135263531, 136367349, 136946500, 139161543, 144116282, 152258577, 160647412, 162037484, 162202698, 177748748, 184819679, 188899568, 198973468, 223554899, 223679655, 223701041, 223705266, 226458274, 241382117, 249868020, 251970989, 252063684, 252451819
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Guanine nucleotide exchange factor (GNEF) | Target Info | Stimulator | [1] |
| Tubulin beta (TUBB) | Target Info | Modulator | [2] | |
| KEGG Pathway | Phagosome | |||
| Gap junction | ||||
| Pathogenic Escherichia coli infection | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| EGFR1 Signaling Pathway | ||||
| Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
| Huntington disease | ||||
| Reactome | Regulation of PLK1 Activity at G2/M Transition | |||
| Loss of Nlp from mitotic centrosomes | ||||
| Recruitment of mitotic centrosome proteins and complexes | ||||
| Loss of proteins required for interphase microtubule organization?from the centrosome | ||||
| Anchoring of the basal body to the plasma membrane | ||||
| WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | |||
| Pathogenic Escherichia coli infection | ||||
| Mitotic G2-G2/M phases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.